9 February 2006

Contents

Antiretrovirals

• SMART study halted due to safety concerns with significantly more AIDS events in the treatment interruption arm

• TMC114 (darunavir) new drug applications submitted to US and European regulatory agencies

Treatment access

• Missing the target: a report on HIV/AIDS treatment access from the frontlines

• New Clinton agreements to lower prices of HIV/AIDS rapid tests and second-line drugs in 50 countries

• WHO adds seven antiretrovirals to list of prequalified HIV drugs

• Ranbaxy launches two new ARVs in India

• FDA tentative approvals: generic oral solutions of nevirapine and d4T

• Amendment to WTO TRIPS agreement makes access to affordable medicines even more bleak: MSF expresses concern that patients the world-over will have to pay the price

• WTO uses AIDS patients to cover up development round failure